Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Peregrine Pharmaceuticals

Peregrine Pharmaceuticals reported $87.32M in Current Liabilities for its fiscal quarter ending in December of 2022.

Current Liabilities Change
Agenus AGEN:US USD 190.9M 1.95M
Amgen AMGN:US USD 14.22B 1.47B
AstraZeneca AZN:LN USD 24.86B 1.43B
Celldex Therapeutics CLDX:US USD 15.22M 3.39M
Eli Lilly LLY:US USD 16.01B 1.13B
GlaxoSmithKline GSK:LN GBP 20.7B 2.11B
Immunogen IMGN:US USD 101.63M 20.23M
Intrexon XON:US USD 46.73M 31.91M
Karyopharm Therapeutics KPTI:US USD 61.56M 10.45M
Lumos Pharma Inc. NLNK:US USD 5.02M 1.69M
MacroGenics MGNX:US USD 45.61M 3M
MannKind MNKD:US USD 81.85M 14.56M
Minerva Neurosciences NERV:US USD 2.5M 1.12M
Novartis NOVN:VX USD 30.55B 1.89B
Novavax NVAX:US USD 1.92B 541.09M
Peregrine Pharmaceuticals PPHM:US USD 87.32M 4.94M
Repligen RGEN:US USD 405.32M 1.12M
Roche Holding ROG:VX CHF 27.24B 170M
Xencor XNCR:US USD 65.06M 1.21M